Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQB365 in Advanced Solid Malignancies With KRAS G12S or G12C Mutations
NCT06720987Phase 1Recruiting
- Sponsor
- Kumquat Biosciences
- Start
- Feb 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KQB365 in solid tumor, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (7 arms), sponsored by Kumquat Biosciences. Primary endpoints: Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities, Recommended Phase 2 Dose up to 35 months and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
KQB365
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06720987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720987.